ClinicalTrials.gg
CompletedNCT00259792Updated Jan 24, 2011

SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults

A Phase 3 interventional study of Budesonide/formoterol Turbuhaler in Asthma, sponsored by AstraZeneca. Completed at 82 sites in France. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
14th of 108
1,000 · median 124
Started
2004
with 10 others
Phase 3
51 of 110
3 open now
Registered
14th of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 14th largest by enrollment of the 108 interventional ones that give a count, is one of 11 that started in 2004, is one of 51 in phase 3, and was the 14th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The purpose of the study is to compare the efficacy of a flexible dose of Symbicort with conventional stepwise treatment according to asthma treatment guidelines in patients with persistent asthma.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minimum of 3 months history of asthma, diagnosed according to the American Thoracic Society (ATS) definition. Prescribed inhaled GCS at a dose of ³400 µg/day and within the approved label for the relevant drug during the last 3 months prior to Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Use of any b-blocking agent, including eye-drops, Use of oral GCS as maintenance treatment, A history of smoking ³ 10 pack years (1 pack year = 1 pack (20 cigarettes) per day for one year or equivalent).
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Time to first severe asthma exacerbation

Secondary outcomes

  1. Number of asthma exacerbations, Mean use of as-needed medication, Prescribed asthma medication, Asthma Control Questionnaire, Satisfaction with Asthma Treatment Questionnaire, Safety: Serious Adverse Events and discontinuations due to adverse events

07

Study locations

82 sites
  • Research Site
    Abbeville, France
  • Research Site
    Agen, France
  • Research Site
    Ajaccio, France
  • Research Site
    Albi, France
  • Research Site
    Ales, France
  • Research Site
    Amberieu En Bugey, France
  • Research Site
    Amiens, France
  • Research Site
    Angers, France
  • Research Site
    Angouleme, France
  • Research Site
    Apt, France
  • Research Site
    Arles, France
  • Research Site
    Aubagne, France
  • Research site
    Avignon, France
  • Research Site
    Avrille, France
  • Research Site
    Bastia, France
  • Research Site
    Bayonne, France
  • Research Site
    Bethune, France
  • Research Site
    Beziers, France
  • Research Site
    Biarritz, France
  • Research Site
    Blois, France
  • Research Site
    Bois Guillaume, France
  • Research Site
    Bordeaux, France
  • Research Site
    Boulogne Billancourt, France
  • Research Site
    Bourgoin Jallieu, France
  • Research Site
    Brest, France
  • Research Site
    Briey, France
  • Research Site
    Bron, France
  • Research Site
    Cabestany, France
  • Research Site
    Cachan, France
  • Research Site
    Caen, France
  • Research Site
    Cagnes Sur Mer, France
  • Research Site
    Cambrai, France
  • Research Site
    Carcassonne, France
  • Research Site
    Castelnau Le Lez, France
  • Research site
    Challans, France
  • Research Site
    Chalons En Champagne, France
  • Research Site
    Champs Sur Marne, France
  • Research Site
    Charleville Mezieres, France
  • Research Site
    Chelles, France
  • Research Site
    Cherbourg Octeville, France
  • Research Site
    Chevilly Larue, France
  • Research Site
    Choisy Le Roi, France
  • Research site
    Cholet, France
  • Research Site
    Colmar, France
  • Research Site
    Cornebarrieu, France
  • Research Site
    Courbevoie, France
  • Research Sites
    Creteil, France
  • Research Site
    Denain, France
  • Research Site
    Dieppe, France
  • Research Site
    Dijon, France
  • Research Site
    Dole, France
  • Research Site
    Epernay, France
  • Research Site
    Epinal, France
  • Research Site
    Ermont, France
  • Research Site
    Etampes, France
  • Research Site
    Fecamp, France
  • Research Site
    Forbach, France
  • Research Site
    Gournay Sur Marne, France
  • Research Site
    Grenoble, France
  • Research Site
    Hagondange, France
  • Research Site
    Hazebrouck, France
  • Research Site
    Henin Beaumont, France
  • Research Site
    Herblay, France
  • Research Site
    Hyeres, France
  • Research Site
    Issy Les Moulineaux, France
  • Research Site
    Joigny, France
  • Research Site
    Juan Les Pins, France
  • Research Site
    La Roche Sur Yon, France
  • Research site
    La Rochelle, France
  • Research Site
    La Teste De Buch, France
  • Research Site
    Lagardelle Sur Leze, France
  • Research Site
    Le Havre, France
  • Research Site
    Le Puy En Velay, France
  • Research site
    Lens, France
  • Research Site
    Les Mureaux, France
  • Research Site
    Libourne, France
  • Research Site
    Lille, France
  • Research site
    Limoges, France
  • Research site
    Loudeac, France
  • Research site
    Luneville, France
  • Research Site
    Lyon, France
  • Research Site
    Marcq En Baroeul, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2005
First posted
Dec 1, 2005
Start
Sep 2004
CompletionActual
Jan 2006
Last update
Jan 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00259792
Lead sponsor
AstraZeneca
First posted
Dec 1, 2005
Start date
Sep 2004
Completion
Jan 2006
Last update
Jan 24, 2011

Study contacts

AstraZeneca France Medical Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion